Search Results
44 results found for "Tudor Oprea"
Posts (36)
- Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of...
September 2022 Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model antibody atezolizumab and nab-paclitaxel has shown clinical activity in advanced TNBC with PD-L1-positive tumor-infiltrating As tumor-associated macrophages (TAMs) serve as major contributors to the immuno-suppressive tumor microenvironment We show that through proper calibration, the model captures the macrophage heterogeneity in the tumor
- Propranolol: A “Pick and Roll” Team Player in Benign Tumors and Cancer Therapies
and inflammation, all of which are influenced by the cellular and molecular microenvironment of the tumor techniques, have been tested to reduce the malignancy and generate a harmful microenvironment for the tumor therapeutic benefits of the β-adrenergic receptor antagonist, propranolol, were described in benign tumors
- Identification of A2BAR as a potential target in colorectal cancer using novel fluorescent GPCR...
Here, using colorectal cancer (CRC) as a model, we explored the gene expression of a panel of GPCRs in tumor live-imaging modalities, and displayed high efficiency when used to label complex 3D cellular systems such as tumor A2BAR as a potential pharmacological tool in CRC, using selective antagonists, finding a reduction in tumor
Other Pages (8)
- Ep 18 with Dr. Yamina Berchiche
Our guests were Maria Waldhoer , Tudor I. Oprea , Thomas Sakmar , Aurelien Rizk & Yaroslav Nikolaev .
- Student Flash Presentations | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
Trabecular Identity Abhishek Kumar Singh Investigating The Role of ADGRB3 Loss of Expression in Brain Tumor Glioblastoma (GBM) is the most prevalent central nervous system tumor in LFS, with TP53 mutations detected member of the BAI1-3 subfamily of adhesion GPCRS, has been observed to have low expression in brain tumors These observations lead me to hypothesize that ADGRB3 functions as a tumor suppressor in the brain, and Standard of care for MB includes tumor resection, chemotherapy, and cranio-spinal radiation.
- Session VI | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
We showed that CD97 (ADGRE5), in particular, drives tumor growth via effects on GBM stem cell self-renewal patient-derived GBM xenografts in the brain of immunodeficient mice resulted in significant reduction of tumor Collectively, these data suggest that ADCs targeting CD97 impair tumor growth in preclinical GBM models As a clinician, he specializes in surgical treatment of brain tumors.